BiotechTube

OSE2101 + Docetaxel

Phase 3Recruiting
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patients With Non-Small Cell Lung Cancer

Conditions

Patients With Non-Small Cell Lung Cancer

Trial Timeline

Dec 3, 2024 → Dec 15, 2028

NCT ID
NCT06472245

About OSE2101 + Docetaxel

OSE2101 + Docetaxel is a phase 3 stage product being developed by OSE Immunotherapeutics for Patients With Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06472245. Target conditions include Patients With Non-Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06472245Phase 3Recruiting

Competing Products

20 competing products in Patients With Non-Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + Epoetin betaChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
41
FK949EAstellas PharmaPhase 1
33
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
ASP8825Astellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP7991Astellas PharmaPhase 1
33
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
ATG-FAstellas PharmaApproved
85
CelecoxibAstellas PharmaPre-clinical
23
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 1
33

Other Products from OSE Immunotherapeutics

OSE2101 + Docetaxel + PemetrexedPhase 3
69
OSE-127 + PlaceboPhase 2
44
FOLFIRI + OSE2101Phase 2
44
FR104Phase 1/2
33
Part A: OSE-279 100mg + Part A: OSE-279 300mg + Part A: OSE-279 600mg + Part B: OSE-279 600 mg and OSE2101 + Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive + Part C: OSE-279 600 mg - HLA-A2 positif + Part C: OSE-279 600 mg - HLA-A2 negativePhase 1/2
33